GlobalData on MSN4d
Biogen proposes acquisition of partner Sage TherapeuticsThe proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Intellia Therapeutics announced its strategic priorities and key anticipated milestones for 2025. However, investors were ...
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...
Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ...
As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...
Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects. Sage, whose shares fell 74.9 per cent last ...
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback